Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Subjects With Autism Spectrum Disorder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Dec 2022
Price :
$35
*
At a glance
- Drugs JNJ 42165279 (Primary)
- Indications Pervasive child development disorders
- Focus Therapeutic Use
- Acronyms Envision
- Sponsors Janssen Research & Development
- 06 Dec 2022 Status changed from active, no longer recruiting to completed.
- 13 Sep 2022 Planned primary completion date changed from 19 Oct 2022 to 11 Nov 2022.
- 13 Sep 2022 Status changed from recruiting to active, no longer recruiting.